Related Experiment Video For Cordyceps militaris capsules
Updated: Jun 11, 2026
Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
Published on: August 24, 2019
Evaluating Cordyceps militaris capsules on post-bronchodilator FEV1 decline in patients with COPD: a study protocol
Siqi Lin1, Tianming Liao1, Feiting Fan1,2
1State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
Background:
Chronic Obstructive Pulmonary Disease (COPD) is characterized by a progressive deterioration of lung function, which occurs at its fastest rate in the early stages (GOLD I-II). Preliminary clinical investigation has suggested that Cordyceps militaris capsules can improve post-bronchodilator forced expiratory volume in 1 s (FEV1) in mild-to-moderate COPD. However, previous studies were limited by the absence of placebo control. Therefore, this trial is designed to evaluate the efficacy and safety of Cordyceps militaris capsules versus placebo in improving post-bronchodilator FEV1 in patients with mild-to-moderate stable COPD.
Methods:
This study is a multi-center, randomized, double-blind, placebo-controlled clinical trial involving 160 eligible patients aged between 40 and 85 years. After a 1-week run-in period, participants are randomized in a 1:1 ratio to receive either Cordyceps militaris capsules or placebo capsules for 24 weeks, and are followed for an additional 24 weeks. The primary outcome measure is the change in post-bronchodilator FEV1. Secondary outcome measures comprise additional lung function parameters, such as pre-bronchodilator FEV1, pre- and post-bronchodilator measures of forced vital capacity (FVC), FEV1/FVC ratio, mid-expiratory flow (MMEF), forced expiratory flow 75% (FEF75), forced expiratory flow 50% (FEF50). In addition, frequency of acute exacerbations, time to the first acute exacerbation, COPD Assessment Test (CAT), Cough and Sputum Assessment Questionnaire (CASA-Q), EuroQol five-dimension five-level questionnaire (EQ-5D-5L), and Modified Medical Research Council dyspnea scale (mMRC) are also included.
Discussion:
This study is designed to evaluate the therapeutic potential of Cordyceps militaris capsules and to provide a traditional Chinese medicine intervention for preserving lung function in mild-to-moderate stable COPD.
Clinical Trial Registration:
https://www.chictr.org.cn/, ChiCTR2400086743, identifier, ChiCTR2400086743.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
01:29Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
01:24Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:20COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...